Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Oncology Reports is a distinguished journal dedicated to advancing knowledge in the field of oncology. Published by Spandidos Publications Ltd, this journal has been a cornerstone in cancer research since its establishment in 1994 and is set to continue its impactful contributions until 2024. With ISSN 1021-335X and E-ISSN 1791-2431, it ranks in the Q2 category in Cancer Research, Medicine (Miscellaneous), and Oncology as of 2023, reflecting its solid standing in the academic community. The journal's current Scopus rankings position it notably within Medicine (Oncology) (#74/404, 81st percentile) and Biochemistry, Genetics and Molecular Biology (Cancer Research) (#67/230, 71st percentile), underscoring its rigorous peer-review process and the quality of its published research. Although not an open-access journal, Oncology Reports remains committed to disseminating vital information to researchers, professionals, and students, ensuring they stay at the forefront of developments in cancer studies. Its comprehensive scope promotes a multidisciplinary approach, encompassing clinical and experimental aspects of oncology, thus serving as an essential resource for those striving to understand and combat cancer.

JCO Global Oncology is a premier open-access journal published by Lippincott Williams & Wilkins, dedicated to the dissemination of high-quality research in the fields of cancer research and oncology. Since its inception in 2020, this journal has rapidly established itself as a vital resource for researchers, healthcare professionals, and students, holding a distinguished position in the Q2 category for both Cancer Research and Oncology based on the latest metrics. With an impressive Scopus rank of #61 out of 636 in General Medicine, the journal is recognized for its rigorous peer-reviewed articles and cutting-edge insights into oncological science. The open-access model ensures that vital research is readily available to a global audience, fostering collaborative advancements in the fight against cancer. JCO Global Oncology explores a broad range of topics and encourages submissions that contribute to the understanding, prevention, and treatment of various malignancies. With its substantial impact and ongoing contributions to the field, it stands as a promising platform for advancing oncological discourse and knowledge.

The United European Gastroenterology Journal, published by John Wiley & Sons Ltd, is a leading publication in the fields of gastroenterology and oncology, boasting a distinguished Q1 ranking in both categories for 2023. With an ISSN of 2050-6406 and an E-ISSN of 2050-6414, this journal serves as a vital platform for disseminating cutting-edge research and innovative practices from 2013 to 2024, supporting the advancement of knowledge in gastrointestinal health and cancer treatment. With a commendable Scopus Rank of 14th out of 167 in gastroenterology and 54th out of 404 in oncology, it emphasizes the significance of impactful research in these critical areas. While currently not an open-access journal, it remains a vital resource for researchers, professionals, and students seeking comprehensive insights and evidence-based approaches to improve patient care and clinical outcomes. The United European Gastroenterology Journal is committed to bridging the gap between research and practice, making it an essential reference for those dedicated to the fields of gastroenterology and oncology.

The Indian Journal of Surgical Oncology, published by SPRINGER INDIA, is a vital source of scholarly research and discourse in the fields of oncology and surgery. Since its inception in 2010, the journal has been dedicated to advancing the science and practice of surgical oncology, providing a platform for researchers, clinicians, and educators to disseminate their findings and insights. With an increasing impact factor, the journal currently ranks in the Q4 category in Oncology and Q3 category in Surgery, reflecting its growing influence in the academic community. The journal maintains a focus on high-quality research, clinical studies, and innovative surgical techniques, fostering knowledge exchange among professionals in India and beyond. Although an open access option is not provided, the journal remains an essential repository of information for anyone engaged in the rapidly evolving fields of surgical oncology. For access to groundbreaking research and updates in the discipline, the Indian Journal of Surgical Oncology continues to be an indispensable resource.

Rehabilitation Oncology, published by Lippincott Williams & Wilkins, is an essential academic journal dedicated to the interdisciplinary field of cancer rehabilitation. Since its inception in 2008, it has provided a platform for illuminating research, clinical practices, and innovative therapies aimed at improving the quality of life for cancer survivors. With an ISSN of 2168-3808 and an E-ISSN of 2381-2427, the journal covers a wide spectrum of topics, making significant contributions across various categories including Oncology, Rehabilitation, and Physical Therapy. Although currently not Open Access, the journal has garnered a notable 2023 Impact Factor status, placing it in the Q3 quadrant across multiple relevant disciplines as per the latest Scopus rankings. This reflects its growing influence in the rehabilitation community and offers vital insights for practitioners and researchers seeking to advance their understanding of patient care post-cancer treatment. With its focus on bridging the gap between research and real-world application, Rehabilitation Oncology serves as a vital resource for healthcare professionals committed to enhancing recovery outcomes in their patients.

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.

Oncology and Therapy, published by SPRINGER, is a distinguished open-access journal that has been dedicated to the dissemination of innovative research in the field of oncology since its inception in 2015. With an ISSN of 2366-1070 and an E-ISSN of 2366-1089, the journal serves as a vital platform for the latest advancements in cancer treatment and therapeutic approaches. Based in Switzerland, this journal is indexed in Scopus, where it currently holds a respectable rank of #236 out of 404 in Medicine - Oncology, placing it in the 41st percentile, indicating its relevance and contribution to the field. Oncology and Therapy is recognized for its rigorous peer-review process and its commitment to open-access publishing, ensuring that high-quality research is accessible to a global audience. The journal’s current categorization in the Q2 quartile highlights its importance and credibility within the oncology community, making it an essential resource for researchers, clinicians, and students aiming to stay at the forefront of cancer research and therapy.